Theravance Biopharma Files 8-K on Financials

Ticker: TBPH · Form: 8-K · Filed: Aug 5, 2024 · CIK: 1583107

Theravance Biopharma, Inc. 8-K Filing Summary
FieldDetail
CompanyTheravance Biopharma, Inc. (TBPH)
Form Type8-K
Filed DateAug 5, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.00001
Sentimentneutral

Sentiment: neutral

Topics: financial-reporting, 8-k

TL;DR

Theravance Biopharma dropped an 8-K on financials, check it out.

AI Summary

Theravance Biopharma, Inc. filed an 8-K on August 5, 2024, to report on its results of operations and financial condition. The filing also includes financial statements and exhibits. The company is incorporated in the Cayman Islands and its principal executive offices are located in South San Francisco, California.

Why It Matters

This 8-K filing provides an update on Theravance Biopharma's operational and financial status, which is crucial for investors to assess the company's performance and future prospects.

Risk Assessment

Risk Level: low — This filing is a routine 8-K reporting financial results and exhibits, with no immediate or significant new risks indicated.

Key Players & Entities

  • Theravance Biopharma, Inc. (company) — Registrant
  • August 5, 2024 (date) — Date of earliest event Reported
  • Cayman Islands (location) — State or Other Jurisdiction of Incorporation
  • 901 Gateway Boulevard South San Francisco , CA 94080 (address) — Principal executive offices
  • 650-808-6000 (phone_number) — Business phone number

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report on Theravance Biopharma, Inc.'s Results of Operations and Financial Condition, and to include Financial Statements and Exhibits.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on August 5, 2024.

Where is Theravance Biopharma, Inc. incorporated?

Theravance Biopharma, Inc. is incorporated in the Cayman Islands.

What is the address of Theravance Biopharma's principal executive offices?

The principal executive offices of Theravance Biopharma, Inc. are located at C/O Theravance Biopharma US, Inc. 901 Gateway Boulevard South San Francisco, CA 94080.

What is the business phone number for Theravance Biopharma, Inc.?

The business phone number for Theravance Biopharma, Inc. is (650) 808-6000.

Filing Stats: 566 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2024-08-05 16:16:13

Key Financial Figures

  • $0.00001 — e on which registered Ordinary Share $0.00001 Par Value TBPH NASDAQ Global Marke

Filing Documents

02. Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition. On August 5, 2024, Theravance Biopharma, Inc. (the "Company") issued a press release and is holding a conference call regarding its financial results for the quarter ended June 30, 2024 and a business update. A copy of the press release is furnished as Exhibit 99.1 to this Current Report and a copy of materials that will accompany the call is furnished as Exhibit 99.2 to this Current Report. The information in Item 2.02 and in Item 9.01 of this Current Report on Form 8-K, including Exhibits 99.1 and 99.2, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Securities Exchange Act of 1934"), or otherwise subject to the liabilities of that Section, nor shall it be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as expressly set forth by specific reference in such a filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. 99.1 Press Release dated August 5, 2024 99.2 Slide deck entitled Second Quarter 2024 Financial Results and Business Update 104 Cover Page Interactive Data File (cover page XBRL tags embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. THERAVANCE BIOPHARMA, INC. Date: August 5, 2024 By: /s/ Aziz Sawaf Aziz Sawaf Senior Vice President and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.